1 – 20 of 32
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2021
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
- 2017
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Long term azathioprine maintenance therapy in ANCA-associated vasculitis : combined results of long-term follow-up data
(
- Contribution to journal › Article
-
Mark
Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides
(
- Contribution to journal › Article
- 2016
-
Mark
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
- 2014
-
Mark
Comparison of phenotype and outcome in microscopic polyangiitis between europe and Japan.
(
- Contribution to journal › Article
- 2013
-
Mark
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
(
- Contribution to journal › Article
-
Mark
Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al Reply
(
- Contribution to journal › Letter
- 2012
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al Reply
(
- Contribution to journal › Letter
-
Mark
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article
-
Mark
Long-term patient survival in ANCA-associated vasculitis
(
- Contribution to journal › Article